Movement disorders associated with chromosomal aberrations diagnosed in adult patients
Abstract
Introduction. Chromosomal aberrations are rare but important causes of various movement disorders. In cases of movement disorders associated with dysmorphic features, multiorgan involvement and/or intellectual disability, the identification of causative chromosomal aberrations should be considered. Aim of the study. The purpose of this article was to summarise clinical findings in six patients with dystonia and two with parkinsonism and identified chromosomal aberrations in a single-centre prospective study. Materials and methods. 15 adult patients with dystonia or parkinsonism were referred to array comparative genomic hybridisation (aCGH) testing from our Department of Neurology between 2014 and 2019. Additionally, one patient had a karyotype examination. Detailed clinical, psychological and radiological diagnostics were performed in each case. Results. Chromosomal aberrations were identified in six patients with dystonia and two with parkinsonism. Two patients were identified with aberrations associated with de Grouchy syndrome. We also reported generalised dystonia in patients with deletion in 3q26.31 and duplication in 3p26.3, as well as dystonia and hypoacusis in a patient with duplication in Xq26.3. One patient was diagnosed with duplication in 21q21.1. Early-onset parkinsonism was a manifestation of deletion in the 2q24.1 region. Late onset parkinsonism was also present in the patient with the most severe aberrations (duplication 1q21.1q44; deletion 10p15.3p15.1; deletion 10q11.21). Conclusions. Dystonia and parkinsonism are possible manifestations of chromosomal aberrations. Chromosomal aberrations should be excluded in patients with early-onset movement disorders and concomitant dysmorphic features and/or intellectual disability. It is important to include this cause of movement disorders in future classifications. aCGH can be a valuable diagnostic tool in the evaluation of movement disorder aetiology.
Keywords: dystoniaParkinson’s diseasechromosomal aberrationsmicroarrayparkinsonism
References
- Albanese A, Bhatia K, Bressman SB, et al. Phenomenology and classification of dystonia: a consensus update. Mov Disord. 2013; 28(7): 863–873.
- Albanese A, Asmus F, Bhatia KP, et al. EFNS guidelines on diagnosis and treatment of primary dystonias. Eur J Neurol. 2011; 18(1): 5–18.
- Berardelli A, Wenning GK, Antonini A, et al. EFNS/MDS-ES recommendations for the diagnosis of Parkinson's disease. European Journal of Neurology. 2012; 20(1): 16–34.
- Yoon WT. Comparison of dystonia between Parkinson's disease and atypical parkinsonism: The clinical usefulness of dystonia distribution and characteristics in the differential diagnosis of parkinsonism. Neurol Neurochir Pol. 2018; 52(1): 48–53.
- Dale RC, Grattan-Smith P, Nicholson M, et al. Microdeletions detected using chromosome microarray in children with suspected genetic movement disorders: a single-centre study. Dev Med Child Neurol. 2012; 54(7): 618–623.
- Miller DT, Adam MP, Aradhya S, et al. Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet. 2010; 86(5): 749–764.
- Lohmann K, Redin C, Tönnies H, et al. Complex and Dynamic Chromosomal Rearrangements in a Family With Seemingly Non-Mendelian Inheritance of Dopa-Responsive Dystonia. JAMA Neurol. 2017; 74(7): 806–812.
- Villafuerte B, Natera-de-Benito D, González A, et al. The Brain-Lung-Thyroid syndrome (BLTS): A novel deletion in chromosome 14q13.2-q21.1 expands the phenotype to humoral immunodeficiency. Eur J Med Genet. 2018; 61(7): 393–398.
- Garraux G, Caberg JH, Vanbellinghen JF, et al. Partial trisomy 4q associated with young-onset dopa-responsive parkinsonism. Arch Neurol. 2012; 69(3): 398–400.
- Mok KY, Sheerin U, Simón-Sánchez J, et al. International Parkinson's Disease Genomics Consortium (IPDGC). Deletions at 22q11.2 in idiopathic Parkinson's disease: a combined analysis of genome-wide association data. Lancet Neurol. 2016; 15(6): 585–596.
- Robak LA, Du R, Yuan Bo, et al. Integrated sequencing and array comparative genomic hybridization in familial Parkinson disease. Neurol Genet. 2020; 6(5): e498.
- Siuda J, Boczarska-Jedynak M, Budrewicz S, et al. Validation of the Polish version of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS). Neurol Neurochir Pol. 2020; 54(5): 416–425.
- de Gr, Turleau C. Clinical Atlas of Human Chromosomes. Wiley Medical: New York. ; 1984.
- Tezzon F, Zanoni T, Passarin MG, et al. Dystonia in a patient with deletion of 18p. Ital J Neurol Sci. 1998; 19(2): 90–93.
- Esposito F, Addor MC, Humm AM, et al. GNAL deletion as a probable cause of dystonia in a patient with the 18p- syndrome. Parkinsonism Relat Disord. 2014; 20(3): 351–352.
- Riva P, Ratti A, Venturin M. The Long Non-Coding RNAs in Neurodegenerative Diseases: Novel Mechanisms of Pathogenesis. Curr Alzheimer Res. 2016; 13(11): 1219–1231.
- Tonkin ET, Smith M, Eichhorn P, et al. A giant novel gene undergoing extensive alternative splicing is severed by a Cornelia de Lange-associated translocation breakpoint at 3q26.3. Hum Genet. 2004; 115(2): 139–148.
- Evers C, Mitter D, Strobl-Wildemann G, et al. Duplication Xp11.22-p14 in females: does X-inactivation help in assessing their significance? Am J Med Genet A. 2015; 167A(3): 553–562.
- Madrigal I, Fernández-Burriel M, Rodriguez-Revenga L, et al. Xq26.2-q26.3 microduplication in two brothers with intellectual disabilities: clinical and molecular characterization. J Hum Genet. 2010; 55(12): 822–826.
- Wirth T, Mariani LL, Bergant G, et al. Loss-of-Function Mutations in NR4A2 Cause Dopa-Responsive Dystonia Parkinsonism. Mov Disord. 2020; 35(5): 880–885.
- Palumbo O, Fischetto R, Palumbo P, et al. De novo microduplication of CHL1 in a patient with non-syndromic developmental phenotypes. Mol Cytogenet. 2015; 8: 66.
- Vissers LE, Veltman JA, van Kessel AdG, et al. Identification of disease genes by whole genome CGH arrays. Hum Mol Genet. 2005; 14 Spec No. 2: R215–R223.
- Fiandaca MS, Lonser RR, Elder JB, et al. Advancing gene therapies, methods, and technologies for Parkinson's Disease and other neurological disorders. Neurol Neurochir Pol. 2020; 54(3): 220–231.
